EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Machine learning driven bioequivalence risk assessment at an early stage of generic drug development

Dejan Krajcar, Dejan Velušček, Iztok Grabnar

European Journal of Pharmaceutics and Biopharmaceutics · 2024

DOI: 10.1016/j.ejpb.2024.114553 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2024. Verfasst von Dejan Krajcar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Lek Pharmaceuticals d.d., A Sandoz Company, Verovskova 57, 1526 Ljubljana, Slovenia; Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7,…. Hauptthemen laut MEDLINE: Therapeutic Equivalency, Machine Learning, Drugs, Generic, Drug Development. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Slovenian Research and Innovation Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bioequivalence risk assessment as an extension of quality risk management lacks examples of quantitative approaches to risk assessment at an early stage of generic drug development. The aim of our study was to develop a model-based approach for bioequivalence risk assessment that uses pharmacokinetic and physicochemical characteristics of drugs as predictors and would standardize the first step of risk assessment. METHODS: The Sandoz in-house bioequivalence database of 128 bioequivalence studies with poorly soluble drugs (23.5% non-bioequivalent) was used to train and validate the model. Four different modeling approaches, random forest, XGBoost, logistic regression and naïve Bayes, were compared. RESULTS: Among the best performing machine learning models, random forest was selected and optimized for the number of features, resulting in an accuracy of 84% on the test data set. The most important features for prediction were those related to solubility (dose number, acid dissociation constant), absorption and elimination rate, effective permeability, variability of pharmacokinetic endpoints, and absolute bioavailability. All features had a conceivable influence on the model predictions. CONCLUSION: The model was used to develop a bioequivalence risk assessment approach to categorize drugs in early development into high, medium or low risk classes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Therapeutic EquivalencyMachine LearningDrugs, GenericDrug DevelopmentRisk AssessmentHumansBiological AvailabilityBayes TheoremSolubility

Stichwörter der Autor:innen

BioequivalenceLogistic regressionRandom forestRisk predictionXGBoost

Substanzen

Drugs, Generic

Autor:innen und Institutionen

  • Lek Pharmaceuticals d.d., A Sandoz Company, Verovskova 57, 1526 Ljubljana, Slovenia; Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia. Electronic address: dejan.krajcar@sandoz.co…
  • Lek Pharmaceuticals d.d., A Sandoz Company, Verovskova 57, 1526 Ljubljana, Slovenia.
  • Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.

Förderung

  • Slovenian Research and Innovation Agency

Zitieren

APA

Krajcar, D., Velušček, D., & Grabnar, I. (2024). Machine learning driven bioequivalence risk assessment at an early stage of generic drug development. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2024.114553

Vancouver

Krajcar D, Velušček D, Grabnar I. Machine learning driven bioequivalence risk assessment at an early stage of generic drug development. European Journal of Pharmaceutics and Biopharmaceutics. 2024. doi:10.1016/j.ejpb.2024.114553

BibTeX
@article{Krajcar2024,
  author = {Krajcar, Dejan and Velušček, Dejan and Grabnar, Iztok},
  title = {Machine learning driven bioequivalence risk assessment at an early stage of generic drug development},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2024},
  doi = {10.1016/j.ejpb.2024.114553}
}
Kostenlos starten →